The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study

Wenxian Wang; Xiaodong Gu; Liping Wang; Xingxiang Pu; Huijing Feng; C. Xu; Guangyuan Lou; Lan Shao; Yibing Xu; Qian Wang; Siyuan Wang; Wenbin Gao; Yiping Zhang; Zhengbo Song

doi:10.1007/s00262-021-03115-y

The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study

Wenxian Wang(Chinese Academy of Sciences), Xiaodong Gu(Chinese Academy of Sciences), Liping Wang, Xingxiang Pu(Central South University), Huijing Feng(Shanxi Academy of Medical Sciences), C. Xu(Nanjing General Hospital of Nanjing Military Command), Guangyuan Lou(Chinese Academy of Sciences), Lan Shao(Chinese Academy of Sciences), Yibing Xu(Chinese Academy of Sciences), Qian Wang(Nanjing University of Chinese Medicine), Siyuan Wang(Shenzhen University Health Science Center), Wenbin Gao(Shenzhen Third People’s Hospital), Yiping Zhang(Chinese Academy of Sciences), Zhengbo Song(Chinese Academy of Sciences)

Cancer Immunology Immunotherapy

November 24, 2021

10.1007/s00262-021-03115-y

Cited by 50Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis